Physician profile
Michael Hatzakis
NPI 1699742114
$754.41
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $167 · 2021: $149 · 2022: $65.16.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $187.46 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $106.62 | 2019-2020 | |
| Amgen INC. | $69.05 | 2019-2022 | |
| Abbvie INC. | $62.15 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $55.37 | 2019 | |
| Mdd US Operations, LLC | $42.51 | 2019 | |
| Zyla Life Sciences, INC. | $33.33 | 2019 | |
| Arbor Pharmaceuticals, INC. | $28.11 | 2019 | |
| Allergan, INC. | $24.76 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.02 | 2022 | |
| Merz North America, INC. | $18.51 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.93 | 2021 | |
| Abbott Laboratories | $17.43 | 2019 | |
| Assertio Therapeutics, INC. | $15.62 | 2019 | |
| Sentynl Therapeutics, INC. | $15.52 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $15.39 | 2021 | |
| Nevro Corp. | $14.83 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $10.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hatzakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.